Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Pan‐coronavirus fusion inhibitors to combat COVID‐19 and other emerging coronavirus infectious diseases
Qiaoshuai Lan, Lijue Wang, Fanke Jiao, et al.
Journal of Medical Virology (2022) Vol. 95, Iss. 1
Open Access | Times Cited: 22

Showing 22 citing articles:

Therapeutic strategies for COVID-19: progress and lessons learned
Guangdi Li, Rolf Hilgenfeld, Richard J. Whitley, et al.
Nature Reviews Drug Discovery (2023) Vol. 22, Iss. 6, pp. 449-475
Open Access | Times Cited: 375
Strategies for the development and approval of COVID-19 vaccines and therapeutics in the post-pandemic period
Danyi Ao, Xuemei He, Jian Liu, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 27
The Design, Synthesis and Mechanism of Action of Paxlovid, a Protease Inhibitor Drug Combination for the Treatment of COVID-19
Miklós Bege, Anikó Borbás
Pharmaceutics (2024) Vol. 16, Iss. 2, pp. 217-217
Open Access | Times Cited: 12
Computational optimization of a pan-coronavirus fusion inhibitory peptide targeting Spike’s heptapeptide repeat region
Peixiang Gao, Shuo Liu, Xiaojing Chi, et al.
Biosafety and Health (2025)
Open Access
Diketopiperazine/piperidine alkaloid as a potential broad-spectrum coronaviral entry inhibitor identified by supercomputer-based virtual screening from a large natural product-based library
Nasim Shahhamzehei, Sara Abdelfatah, Ejlal A. Omer, et al.
Biomedicine & Pharmacotherapy (2025) Vol. 183, pp. 117841-117841
Closed Access
SARS‐CoV‐2 Omicron XBB subvariants exhibit enhanced fusogenicity and substantial immune evasion in elderly population, but high sensitivity to pan‐coronavirus fusion inhibitors
Shuai Xia, Fanke Jiao, Lijue Wang, et al.
Journal of Medical Virology (2023) Vol. 95, Iss. 3
Open Access | Times Cited: 14
Viral Rebound After Antiviral Treatment: A Mathematical Modeling Study of the Role of Antiviral Mechanism of Action
A. Chiarelli, Hana M. Dobrovolny
Interdisciplinary Sciences Computational Life Sciences (2024) Vol. 16, Iss. 4, pp. 844-853
Closed Access | Times Cited: 3
Phenothiazines Inhibit SARS-CoV-2 Entry through Targeting Spike Protein
Taizhen Liang, Shiqi Xiao, Ziyao Wu, et al.
Viruses (2023) Vol. 15, Iss. 8, pp. 1666-1666
Open Access | Times Cited: 6
Low-sugar universal mRNA vaccine against coronavirus variants with deletion of glycosites in the S2 or stem of SARS-CoV-2 spike messenger RNA (mRNA)
Cheng‐Wei Cheng, Chung‐Yi Wu, Szu‐Wen Wang, et al.
Proceedings of the National Academy of Sciences (2023) Vol. 120, Iss. 49
Open Access | Times Cited: 6
4-(3-Phenylsulfonylindol-2-yl)-1-(pyridin-2-yl)piperazinyl-methanones as Potent Inhibitors of both SARS-CoV-2 and HCoV-OC43 Viruses
Michela Puxeddu, Manuela Donalisio, Joachim J. Bugert, et al.
ACS Infectious Diseases (2024) Vol. 10, Iss. 9, pp. 3158-3175
Closed Access | Times Cited: 1
Virtual Screening-Based Peptides Targeting Spike Protein to Inhibit Porcine Epidemic Diarrhea Virus (PEDV) Infection
Qian Xu, Fangyu Wang, Wenqiang Jiao, et al.
Viruses (2023) Vol. 15, Iss. 2, pp. 381-381
Open Access | Times Cited: 4
An Adjustable Adjuvant STINGsome for Tailoring the Potent and Broad Immunity Against SARS‐CoV‐2 and Monkeypox Virus via STING and Necroptosis
Jun Wu, Guan‐Jie Chen, Chen‐Yuan Fan, et al.
Advanced Functional Materials (2023) Vol. 33, Iss. 50
Open Access | Times Cited: 4
Bioinformatic analysis of the S protein of human respiratory coronavirus
Zheng Niu, Shasha Xu, JingYi Zhang, et al.
Molecular Phylogenetics and Evolution (2023) Vol. 181, pp. 107704-107704
Open Access | Times Cited: 3
Clinical development of antivirals against SARS-CoV-2 and its variants
Qiaoshuai Lan, Yan Yan, Guangxu Zhang, et al.
Current Research in Microbial Sciences (2023) Vol. 6, pp. 100208-100208
Open Access | Times Cited: 2
Peptide S4 is an entry inhibitor of SARS-CoV-2 infection
Zhiyu Liang, Jiamei Wang, Huan Zhang, et al.
Virology (2024) Vol. 597, pp. 110149-110149
Closed Access
Identification of nitrile-containing isoquinoline-related natural product derivatives as coronavirus entry inhibitors in silico and in vitro
Nasim Shahhamzehei, Sara Abdelfatah, Hannah Sabeth Schwarzer-Sperber, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 180, pp. 117517-117517
Open Access
Exploring the treatment of SARS-CoV-2 with modified vesicular stomatitis virus
Nishnath Polavarapu, Madison Doty, Hana M. Dobrovolny
Journal of Theoretical Biology (2024), pp. 111959-111959
Closed Access
Fear of COVID-19 Diagnosis and Cannabis Use Patterns Among Adults with Chronic Health Conditions: Results from COVID-19 Cannabis Health Study
Bria-Necole Diggs, Amrit Baral, WayWay M. Hlaing, et al.
Journal of Psychoactive Drugs (2024), pp. 1-10
Closed Access
Utilization of Antiviral Peptides in Treating Coronavirus Infection: An Overview
Qian Xu, Fangyu Wang, Hua Feng, et al.
International Journal of Peptide Research and Therapeutics (2024) Vol. 31, Iss. 1
Closed Access
In silico design and discovery of pan coronavirus small molecule anti-virals targeting 3CL PRO protease
Satish Kumar Manjhi, Aman Achuthan Kattuparambil, Bibhudutta Mishra, et al.
Journal of Biomolecular Structure and Dynamics (2024), pp. 1-18
Closed Access
Mathematical Modeling of Virus-Mediated Syncytia Formation: Past Successes and Future Directions
Hana M. Dobrovolny
Results and problems in cell differentiation (2023), pp. 345-370
Closed Access | Times Cited: 1
Page 1

Scroll to top